



Issuer Hansa Biopharma AB

Holder

Redmile Group, LLC

Instrument

Instrument Stamaktier SE0002148817

Before the transaction

Shares 12,209,214
Voting rights 12,209,214

Transaction

Reason for major shareholding notification Corporate action
Date 28/06/2024
Limit for number of shares 20 %
Limit for number of votes 20 %

After the transaction

Quantity

Shares 12,209,214
Directly held voting rights 0
Indirectly held voting rights 12,209,214

Percentage

Directly held shares 18.00391 %
Directly held voting rights 0 %
Indirectly held voting rights 18.00391 %

Resulting distribution of total holdings

	Percentage of voting rights:	Number of underlying shares:
Shares	18.00391 %	12,209,214

Instruments - FITA Ch. 4, section 2, first paragraph, line 2

Instruments - FITA Ch. 4, section 2, first paragraph, line 3

- Physically settled		
- Cash settled	1.39715 %	947,470
Total	19.40106 %	13,156,684

Chain of controlling companies

Voting rights	%	Voting rights	Company
643,700	0.94921		RedCo I, LP
9,445,764	13.92888		Redmile Biopharma Investments III, LP
31,063	0.04581		Redmile Capital Offshore II Master Fund, Ltd.
405,517	0.59798		Redmile Capital Offshore II Master Fund, Ltd. (Strategic Sleeve)
1,824,430	2.69033		Redmile Strategic Long Only Trading Sub, Ltd.
806,210	1.18885		Redmile Strategic Trading Sub, Ltd.

Group total holdings

Voting rights 13,156,684
Percentage of voting rights 19.40106

Notes (other relevant informations according to law)

On 28 June 2024 Hansa Biopharma AB (the “Issuer”) announced a new number of shares and votes following corporate actions that had taken place during June. Due to the new number of shares and votes, Redmile Group, LLC’s (the “Group”) aggregate percentage of votes and percentage of shares in the Issuer has passively, without any action by the Group, fallen below the 20% threshold.

Published

02/07/2024 17:33

Contact

Name Stefan Berglöf
Phone 0709725490 Email stefan.berglof@walthon.se

CLOSE PRINT